Clinical Trial Update: INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) [Phase 1]

View source ↗

Summary

Phase 1 trial CITADEL-112 evaluating INCB050465 in combination with Rituximab, Bendamustine with Rituximab, or Ibrutinib in previously treated B-cell lymphoma h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• INCB050465
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Incyte Corporation | Conditions: B-cell Lymphoma | Phase 1 | Status: COMPLETED